Nissan Got Rid of Carlos Ghosn. The Way It Did So May Prove Costly.

The Japanese carmaker’s public accounting of its internal problems could provide a handy road map for lawyers seeking payback for investor losses.

After the arrest last year of its chairman, Carlos Ghosn, Nissan has made a very public accounting of its management failures, from a lack of strong internal checks and balances to board meetings that lasted only 20 minutes.

That frankness may play well with the Japanese public and with prosecutors, who have charged the company and Mr. Ghosn with financial wrongdoing. But Nissan’s disclosure of its problems at the top could cost it dearly, and deliver a potential gold mine for the lawyers who squeeze multimillion-dollar settlements out of corporations accused of wrongdoing. read more »

Document reveals how Facebook downplayed early Cambridge Analytica concerns

Internal correspondence provides new insight into how Facebook staff reacted to concerns about use of user data by political campaign consultants

Document reveals how Facebook downplayed early Cambridge Analytica concerns

Internal correspondence provides new insight into how Facebook staff reacted to concerns about use of user data by political campaign consultants. read more »

Illinois patient’s death may be first in US tied to vaping

Illinois health officials said Friday that a patient who contracted a serious lung disease after vaping has died, which could make it the first death in the United States linked to the smoking alternative that has become popular with teens and young adults.

The Illinois Department of Public Health said in a news release that the patient, who was between 17 and 38 years old, had been hospitalized after falling ill following vaping, though it didn’t give other information about the person, including the patient’s name, hometown or date of death. read more »

Humana Accuses Mallinckrodt of ‘Outrageous’ Acthar Price Gouging

Humana Inc. has accused Mallinckrodt PLC of overcharging for its multiple sclerosis drug Acthar by more than 97,000% in “one of the most outrageous price-gouging schemes in the history of American medicine.”

The drug had a “modest” price between 1952 and 2001, according to the insurer’s antitrust lawsuit. Then Questcor Pharmaceuticals, which was later acquired by Mallinckrodt, bought the “unprofitable and largely outdated drug for $100,000 plus modest royalties” and began jacking up the price dramatically. It was up from $40 in 2001 to $39,000 by 2018, Humana claims. read more »